By Paul Armentano, NORML Deputy Director More than nine in ten pediatric oncology providers with opinions favor patients’ access to cannabis therapy, according to survey
More and more people are using medical marijuana every day across the globe. As the stigma surrounding cannabis use continues to erode, I expect that
By Paul Armentano, NORML Deputy Director Fewer adolescents are consuming cannabis; among those who do, fewer are engaging in problematic use of the plant, according
One of the first things that marijuana opponents offer up when railing against cannabis is to say ‘there needs to be more research first.’ Don’t
While doing research for an article being featured in print later this year, I’ve accumulated a nice little body of quotes and research regarding the
Marijuana opponents go to the ‘what about the youth’ argument early and often. They always have, and they probably always will. Opponents will try hard
One of my favorite organizations is the Gridiron Cannabis Coalition. Members like former NFL player Kyle Turley are doing big things to push cannabis reform
Whether you are a fan of sports or not, you should be a fan of Eugene Monroe. Eugene Monroe currently plays for the Baltimore Ravens
There is a growing movement in sports to normalize cannabis consumption by athletes for medical purposes. Athletes of all levels endure a lot of aches,
There are not a lot of studies out there that deal with marijuana and pregnancy. It’s a very touchy subject. However, it’s something that definitely
By Paul Armentano, NORML Deputy Director Cannabis-influenced driving performance is significantly different from alcohol-induced driving behavior, according to driving simulator data published in the Journal
By Paul Armentano, NORML Deputy Director The enactment of statewide laws permitting the physician-authorized use of cannabis therapy has not stimulated increases in marijuana use
By Paul Armentano, NORML Deputy Director The long-term, daily use of cannabis is associated with improved analgesia and reduced opioid use in patients with treatment-resistant
By Paul Armentano, NORML Deputy Director A report published last fall claiming that an estimated three in ten consumers of cannabis suffer from a ‘use
This is a notice of a conference of significance in the medical cannabis field. The Research Summit will be held on March 22-23 at the Natcher
By Paul Armentano, NORML Deputy Director Marijuana use by adolescents is not associated with lower IQ or poorer educational performance once adjustments are made for
By Paul Armentano, NORML Deputy Director Marijuana consumers do not typically use cannabis and alcohol in combination with one another, regardless of whether they are
I received the following press release. Curious to see what Kevin Sabet has to say about this one: The results of an annual survey of
By Paul Armentano, NORML Deputy Director The enactment of statewide laws permitting the use of cannabis for therapeutic purposes is associated with an annual reduction
By Paul Armentano, NORML Deputy Director Cannabinoids are safe and effective for the treatment of chronic pain, according to the results of a systematic review
By Paul Armentano, NORML Deputy Director Current consumers of cannabis are 50 percent less likely to suffer from metabolic syndrome as compared to those who
Gallup has conducted a poll every year since 1969 asking Americans if they support marijuana legalization. In 1969, support was at just 12%. That number
Today, Americans for Safe Access (ASA) released, “Where Will Patients Obtain Their Medicine?” a white paper on the impact of medical cannabis dispensaries on patients,
By Paul Armentano, NORML Deputy Director Patients who possess legal access to cannabis frequently substitute it in place of alcohol and prescription drugs, according to
